Tele: 561.316.3330
Breaking Medical Device News

Tuesday, September 21, 2021


HomeEXECUTIVESJoe Turk Named President for Fresenius Medical Care North America Renal Therapies Group

Joe Turk Named President for Fresenius Medical Care North America Renal Therapies Group

Fresenius Medical Care North America (FMCNA), the nation’s leading provider of kidney care products, announced today that Joseph (Joe) Turk has been named President for the company’s Renal Therapies Group.

In his new role, Joe Turk will be responsible for overseeing Renal Products and Pharmaceutical operations, including sales, clinical support, product marketing and management, customer and technical services, and regulatory affairs.

Having previously served as FMCNA’s President of Home and Critical Care Therapies, these expanded responsibilities align the company’s products teams into one organization – with a focus on efficiently and effectively delivering new technologies to support people living with kidney disease.

“Joe’s decades of strategy and market development experience have been critical in expanding our footprint and technologies in home dialysis and critical care since he joined us as part of the NxStage merger in 2019,” said Bill Valle, Chief Executive Officer, FMCNA. “Joe’s leadership will be instrumental as we focus on better leveraging best practices across divisions for the benefit of our customers, partners, field teams, and most importantly our patients.”

Turk succeeds Mark Costanzo, who recently retired as President of FMCNA’s Renal Therapies Group.

“I am thrilled to bring our exceptional teams together at this important time,” said Turk. “We have an incredible opportunity as the market leader to work together to ensure we’re providing the highest quality care and renal products to the patients we are privileged to serve.”

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

FDA Authorizes Software that Can Help Identify Prostate Cancer

The software is called Paige Prostate and is compatible for use with slide images that have been digitized using a scanner.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

By using this website you agree to accept Medical Device News Magazine Privacy Policy